First Wave BioPharma, Inc. (FWBI) |
|
5.43 -0.25 (-4.4%)
|
01-27 16:00 |
|
Open: |
5.6 |
Pre. Close: |
5.68 |
|
High:
|
5.82 |
Low:
|
5.2 |
|
Volume:
|
429,420 |
Market Cap:
|
5(M) |
|
|
|
Technical analysis |
as of: 2023-01-27 4:44:45 PM |
|
Overall:
|
 |
| Stoxline posted a NEUTRAL today, same as yesterday. Current trend continues, but could change at anytime. It is not a good time to buy or sell. |
| Target: |
Six months: 8.73 One year: 10.2 |
| Support: |
Support1: 3.12 Support2: 0.43 |
| Resistance: |
Resistance1: 7.48 Resistance2: 8.73 |
| Pivot: |
3.02  |
| Moving Average: |
MA(5): 5.09 MA(20): 2.5
MA(100): 1.48 MA(250): 10.91  |
| MACD: |
MACD(12,26): 1.2 Signal(9): 0.8 |
| Stochastic oscillator: |
%K(14,3): 71.4 %D(3): 75.6 |
| RSI: |
RSI(14): 80.1 |
| 52-week: |
High: 49.79 Low: 0.23 |
| Average Vol(K): |
3-Month: 1,201 (K) 10-Days: 3,041 (K) |
|
Price, moving averages and Bollinger Bands |
|
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and NEUTRAL in mid-long term.[ FWBI ] has closed below upper band by 21.3%. Bollinger Bands are 475.6% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 7 days. This is a sign that the current trend might continue. |
|
|
Stock Price Prediction |
Update at 5:00pm EST |
|
If tomorrow:
|
Open lower
|
Open higher
|
|
High:
|
5.83 - 5.86 |
5.86 - 5.89 |
|
Low:
|
5.13 - 5.16 |
5.16 - 5.19 |
|
Close:
|
5.38 - 5.44 |
5.44 - 5.49 |
|
Company Description |
|
First Wave BioPharma, Inc., a clinical-stage biopharmaceutical company, engages in the research and development of targeted and non-systemic therapies for the treatment of patients with gastrointestinal diseases. Its product candidates include niclosamide, an oral small molecule with anti-viral and anti-inflammatory properties; and the biologic adrulipase, a recombinant lipase enzyme designed to enable the digestion of fats and other nutrients. The company develops FW-COV, which is in Phase II clinical trials for the treatment of severe acute respiratory syndrome coronavirus 2 gastrointestinal infections; FW-UP, which is in Phase II clinical trials for the treatment ulcerative proctitis and ulcerative proctosigmoiditis; FW-ICI-AC for immune checkpoint inhibitor-associated colitis and diarrhea in advanced stage oncology patients; and FW-UC, which is in Phase Ib/IIa clinical trials for the treatment of ulcerative proctitis and ulcerative proctosigmoiditis. It also develops FW-CD, which has completed Phase I clinical trials for Crohn's disease; and adrulipase, an oral, non-systemic, and biologic capsule for the treatment of exocrine pancreatic insufficiency in patients with cystic fibrosis and chronic pancreatitis. The company was formerly known as AzurRx BioPharma, Inc. and changed its name to First Wave BioPharma, Inc. in September 2021. First Wave BioPharma, Inc. was incorporated in 2014 and is headquartered in Boca Raton, Florida. |
Headline News |
Wed, 25 Jan 2023
FWBI Blasts Up on Expansion Potential - TipRanks
Wed, 25 Jan 2023
Why Is First Wave BioPharma (FWBI) Stock Up 30% Today? - InvestorPlace
Wed, 25 Jan 2023
First Wave BioPharma Inc (FWBI) Stock Gains 21.49% This Week: Is It a Good Pick? - InvestorsObserver
Thu, 19 Jan 2023
Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and ... - InvestorPlace
Tue, 17 Jan 2023
FWBI Soars on FDA Review for Adrulipase; Street Sees 5x Upside - TipRanks
Mon, 09 Jan 2023
Do Traders Think First Wave BioPharma Inc (FWBI) Can Keep Climbing Monday? - InvestorsObserver
|
Financial Analysis |
| Price to Book Value: |
Neutral |
| P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
| Price to Earnings: |
Neutral |
| PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
| Discounted cash flow: |
Outperform |
| DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
| Return on Assets: |
Outperform |
| ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
| Return on Equity: |
Underperform |
| ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
| Debt to Equity: |
Underperform |
| evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
|
|
|
|
|
|
| Free Technical Analysis Charts
|
|
|
Stock Basics & Statistics |
| Exchange: NASDAQ |
| Sector: Healthcare |
| Industry: Biotechnology |
| Shares Out. |
6 (M) |
| Shares Float |
6 (M) |
|
% Held by Insiders
|
0.1 (%) |
|
% Held by Institutions
|
1.9 (%) |
|
Shares Short
|
174 (K) |
|
Shares Short P.Month
|
534 (K) |
Stock Financials |
|
EPS
|
-5.68 |
|
EPS Est Next Qtl
|
0 |
|
EPS Est This Year
|
0 |
|
EPS Est Next Year
|
0 |
|
Book Value (p.s.)
|
-1 |
|
Profit Margin (%)
|
0 |
|
Operating Margin (%)
|
0 |
|
Return on Assets (ttm)
|
-140.7 |
|
Return on Equity (ttm)
|
0 |
|
Qtrly Rev. Growth
|
0 |
|
Gross Profit (p.s.)
|
0 |
|
Sales Per Share
|
0 |
|
EBITDA (p.s.)
|
-3.29 |
|
Qtrly Earnings Growth
|
0 |
|
Operating Cash Flow
|
-23 (M) |
|
Levered Free Cash Flow
|
-34 (M) |
Stock Valuations |
|
PE Ratio
|
-0.96 |
|
PEG Ratio
|
0 |
|
Price to Book value
|
-5.49 |
|
Price to Sales
|
0 |
|
Price to Cash Flow
|
-1.4 |
Stock Dividends |
|
Dividend
|
0 |
|
Forward Dividend
|
0 |
|
Dividend Yield
|
0% |
|
Dividend Pay Date
|
Invalid DateTime. |
|
Ex-Dividend Date
|
Invalid DateTime. |
|
Your Ad Here
|
|
